title: Academy of Medicine Singapore-Ministry of Health clinical practice guidelines: Autism Spectrum Disorders in pre-school children.
abstract: The Academy of Medicine Singapore (AMS) and the Ministry of Health (MOH) publish clinical practice guidelines to provide doctors and patients in Singapore with evidence-based guidance on managing important medical conditions. This article reproduces the introduction and executive summary (with recommendations from the guidelines) from the AMS-MOH clinical practice guidelines on Autism Spectrum Disorders (ASD), for the information of readers of the Singapore Medical Journal. Chapters and page numbers mentioned in the reproduced extract refer to the full text of the guidelines, which are available from the Ministry of Health website (http://www.moh. gov.sg/mohcorp/publications.aspx?id=24048). The recommendations should be used with reference to the full text of the guidelines. Following this article are multiple choice questions based on the full text of the guidelines.
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000069445:Atomoxetine Hydrochloride; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use; D002659:Child Development Disorders, Pervasive / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology / Q000628:therapy; D002675:Child, Preschool; D018492:Dopamine Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008403:Mass Screening; D008774:Methylphenidate / Q000009:adverse effects / Q000627:therapeutic use; D000077152:Olanzapine; D011379:Prognosis; D011437:Propylamines / Q000009:adverse effects / Q000627:therapeutic use; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D012846:Singapore / Q000453:epidemiology
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000069445:Atomoxetine Hydrochloride; D001569:Benzodiazepines; D000697:Central Nervous System Stimulants; D018492:Dopamine Antagonists; D008774:Methylphenidate; D000077152:Olanzapine; D011437:Propylamines; D018967:Risperidone; D017367:Selective Serotonin Reuptake Inhibitors